Cerlapirdine
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • N,N-dimethyl-3-[(3-naphthalen-1-ylsulfonyl-2H-indazol-5-yl)oxy]propan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC22H23N3O3S
Molar mass409.50 g·mol−1
3D model (JSmol)
  • CN(C)CCCOc4ccc3[nH]nc(S(=O)(=O)c1cccc2ccccc12)c3c4
  • InChI=1S/C22H23N3O3S/c1-25(2)13-6-14-28-17-11-12-20-19(15-17)22(24-23-20)29(26,27)21-10-5-8-16-7-3-4-9-18(16)21/h3-5,7-12,15H,6,13-14H2,1-2H3,(H,23,24)
  • Key:NXQGEDVQXVTCDA-UHFFFAOYSA-N

Cerlapirdine (USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which was under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia.[1] In a phase II clinical trial it demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events,[2] but no further development has occurred since 2011.[3]

It exerts its effects by acting as a selective 5-HT6 receptor antagonist.[1]

See also

References

  1. 1 2 Codony X, Vela JM, Ramírez MJ (February 2011). "5-HT(6) receptor and cognition". Current Opinion in Pharmacology. 11 (1): 94–100. doi:10.1016/j.coph.2011.01.004. hdl:10171/18451. PMID 21330210.
  2. ↑ Franco Borsini (2011). International review of neurobiology: Pharmacology of 5-HT6 receptors. Part 2. Academic Press. p. 5. ISBN 978-0-12-385902-0. Retrieved 25 October 2011.
  3. ↑ Drug Profile: Cerlapirdine
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.